The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Acyclic nucleoside phosphonates: a key class of antiviral drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
Elion, G. B., Furman, P. A., Fyfe, J. A., Miranda, P. D., Beauchamp, L., & Schaeffer, H. J. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5716 · Cited by 1,591
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group
Schaeffer, H. J., Beauchamp, L., de Miranda, P., Elion, G. B., Bauer, D. J., & Collins, P. (1978) · Nature · doi:10.1038/272583a0 · Cited by 1,140
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Werle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905
A novel selective broad-spectrum anti-DNA virus agent
Clercq, E. D., Holý, A., Rosenberg, I., Sakuma, T., Balzarini, J., & Maudgal, P. C. (1986) · Nature · doi:10.1038/323464a0 · Cited by 764
Self-citationAngus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W., Gibbs, C., Brosgart, C., Colledge, D., Edwards, R., Ayres, A., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00939-9 · Cited by 564
Prevention of SIV Infection in Macaques by ( R )-9-(2-Phosphonylmethoxypropyl)adenine
Tsai, C.-C., Follis, K. E., Sabo, A., Beck, T. W., Grant, R. F., Bischofberger, N., Benveniste, R. E., & Black, R. (1995) · Science · doi:10.1126/science.270.5239.1197 · Cited by 563
Peters, M. G., Hann, H. W., Martin, P., Heathcote, E. J., Buggisch, P., Rubin, R., Bourliere, M., Kowdley, K., Trepo, C., Gray, D. F., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.051 · Cited by 552
Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines
Clercq, E. D., Sakuma, T., Baba, M., Pauwels, R., Balzarini, J., Rosenberg, I., & Holý, A. (1987) · Antiviral Research · doi:10.1016/s0166-3542(87)80004-9 · Cited by 515
Self-citationvan Bömmel, F., Wünsche, T., Mauss, S., Reinke, P., Bergk, A., Schürmann, D., Wiedenmann, B., & Berg, T. (2004) · Hepatology · doi:10.1002/hep.20464 · Cited by 389
Lalezari, J. P., Stagg, R. J., Kuppermann, B. D., Holland, G. N., Kramer, F., Ives, D. V., Youle, M., Robinson, M. R., Drew, W. L., & Jaffe, H. S. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-4-199702150-00001 · Cited by 372
De Clercq, E. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.4.569-596.2003 · Cited by 369
Karras, A., Lafaurie, M., Furco, A., Bourgarit, A., Droz, D., Sereni, D., Legendre, C., Martinez, F., & Molina, J. (2003) · Clinical Infectious Diseases · doi:10.1086/368314 · Cited by 361
Lee, W. A., He, G.-X., Eisenberg, E., Cihlar, T., Swaminathan, S., Mulato, A., & Cundy, K. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1898-1906.2005 · Cited by 338
Kedes, D. H., & Ganem, D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119380 · Cited by 316
Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir
Cundy, K. C. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936020-00004 · Cited by 303
Cidofovir in the treatment of poxvirus infections
De Clercq, E. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00008-6 · Cited by 283
Renal Tubular Dysfunction Associated With Tenofovir Therapy: Report of 7 Cases
Peyri??re, H., Reynes, J., Rouanet, I., Daniel, N., de Boever, C. M., Mauboussin, J.-M., Leray, H., Moachon, L., Vincent, D., & Salmon-C??ron, D. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200403010-00007 · Cited by 262
Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents
Pauwels, R., Balzarini, J., Schols, D., Baba, M., Desmyter, J., Rosenberg, I., Holy, A., & De Clercq, E. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.7.1025 · Cited by 256
Dore, G. J., Cooper, D. A., Pozniak, A. L., DeJesus, E., Zhong, L., Miller, M. D., Lu, B., Cheng, A. K., & Teams, T. 9. A. 9. S. (2004) · The Journal of Infectious Diseases · doi:10.1086/380398 · Cited by 253
Naesens, L., Snoeck, R., Andrei, G., Balzarini, J., Neyts, J., & De Clercq, E. (1997) · Antiviral Chemistry and Chemotherapy · doi:10.1177/095632029700800101 · Cited by 243
Snoeck, R., Sakuma, T., De Clercq, E., Rosenberg, I., & Holy, A. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.12.1839 · Cited by 223
Balzarini, J., Naesens, L., Herdewijn, P., Rosenberg, I., Holy, A., Pauwels, R., Baba, M., Johns, D. G., & De Clercq, E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.1.332 · Cited by 219
Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus
Chou, S., Lurain, N. S., Thompson, K. D., Miner, R. C., & Drew, W. L. (2003) · The Journal of Infectious Diseases · doi:10.1086/375743 · Cited by 198
Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection: A Randomized Trial
Squires, K., Pozniak, A. L., Pierone, G., Steinhart, C. R., Berger, D., Bellos, N. C., Becker, S. L., Wulfsohn, M., Miller, M. D., Toole, J. J., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-5_part_1-200309020-00006 · Cited by 198
Renal safety of tenofovir in HIV treatment-experienced patients
Izzedine, H., Isnard-Bagnis, C., Hulot, J. S., Vittecoq, D., Cheng, A., Jais, C. K., Launay-Vacher, V., & Deray, G. (2004) · AIDS · doi:10.1097/00002030-200404300-00019 · Cited by 173
Gallant, J. E., & Deresinski, S. (2003) · Clinical Infectious Diseases · doi:10.1086/378068 · Cited by 162
Structures of HIV-1 RT–DNA complexes before and after incorporation of the anti-AIDS drug tenofovir
Tuske, S., Sarafianos, S. G., Clark, A. D., Ding, J., Naeger, L. K., White, K. L., Miller, M. D., Gibbs, C. S., Boyer, P. L., Clark, P., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb760 · Cited by 161
Deval, J., White, K. L., Miller, M. D., Parkin, N. T., Courcambeck, J., Halfon, P., Selmi, B., Boretto, J., & Canard, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308806200 · Cited by 159
Antiadenovirus Activities of Several Classes of Nucleoside and Nucleotide Analogues
Naesens, L. M. J., Lenaerts, L., Andreï, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1010-1016.2005 · Cited by 156
Margot, N., Isaacson, E., McGowan, I., Cheng, A., Schooley, R. T., & Miller, M. D. (2002) · AIDS · doi:10.1097/00002030-200206140-00004 · Cited by 146
Smee, D. F., Sidwell, R. W., Kefauver, D., Bray, M., & Huggins, J. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1329-1335.2002 · Cited by 139
Lacy, S. A., Hitchcock, M. J. M., Lee, W. A., Tellier, P., & Cundy, K. C. (1998) · Toxicological Sciences · doi:10.1093/toxsci/44.2.97 · Cited by 136
Rollot, F., Nazal, E.-M., Chauvelot‐Moachon, L., Kelaïdi, C., Daniel, N., Saba, M., Abad, S., & Blanche, P. (2003) · Clinical Infectious Diseases · doi:10.1086/379829 · Cited by 131
Abdulkarim, B., Sabri, S., Deutsch, É., Chagraoui, H., Maggiorella, L., Thierry, J., Eschwège, F., Vainchenker, W., Chouaı̈b, S., & Bourhis, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205006 · Cited by 130
Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model
Buller, R. M. L., Owens, G., Schriewer, J. M., Melman, L. M., Beadle, J. R., & Hostetler, K. Y. (2004) · Virology · doi:10.1016/j.virol.2003.11.015 · Cited by 129
Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure
Rifkin, B. S., & Perazella, M. A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.03.025 · Cited by 114
Clercq, E. D., Holý, A., & Rosenberg, I. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.2.185 · Cited by 111
Self-citationShen, Y., Zhukovskaya, N. L., Zimmer, M. I., Soelaiman, S., Bergson, P., Wang, C.-R., Gibbs, C. S., & Tang, W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306552101 · Cited by 109
Tenofovir-related nephrotoxicity in HIV-infected patients
Barrios, A., García-Benayas, T., González‐Lahoz, J., et al. (2004) · AIDS · doi:10.1097/00002030-200404090-00019 · Cited by 109
Cihlář, T., Fuller, M. D., Mulato, A. S., et al. (1998) · Virology · doi:10.1006/viro.1998.9299 · Cited by 92
Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections
Clercq, E. D. (2003) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.1.1.21 · Cited by 84
Self-citationClercq, E. D., Andreï, G., Balzarini, J. M., Leyssen, P., Naesens, L. M. J., Neyts, J. H., Pannecouque, C. C., Snoeck, R., Ying, C., Hocková, D., et al. (2005) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1081/ncn-200059772 · Cited by 82
Self-citationTenofovir Resistance and Resensitization
Wolf, K., Walter, H., Beerenwinkel, N., Keulen, W., Kaiser, R., Hoffmann, D. E., Lengauer, T., Selbig, J., Vandamme, A., Korn, K., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3478-3484.2003 · Cited by 82
Aliphatic analogues of nucleosides, nucleotides, and oligonucleotides
Holý, A. (1975) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc19750187 · Cited by 74
Self-citationEfficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia
Neyts, J. H., Leyssen, P., Verbeken, E. K., & Clercq, E. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2267-2273.2004 · Cited by 65
Self-citationGallant, J. E., Staszewski, S., Pozniak, A., DeJesus, E., Suleiman, J. M. A. H., Miller, M. D., Coakley, D. F., Lu, B., Toole, J. J., & Cheng, A. (2004) · Cited by 62
Aliphatic analogues of nucleotides: synthesis and affinity towards nucleases
Holý, A., & Gs, I. (1974) · Nucleic Acids Research · doi:10.1093/nar/1.1.19 · Cited by 42
Self-citationCutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir
Quenelle, D. C., COLLINS, D., & KERN, E. (2004) · Antiviral Research · doi:10.1016/j.antiviral.2004.02.003 · Cited by 40
Tenofovir Diphosphate Is a Poor Substrate and a Weak Inhibitor of Rat DNA Polymerases α, δ, and ε*
Birkuš, G., Hájek, M., Kramata, P., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1610-1613.2002 · Cited by 39
Oral Formulations of Adefovir Dipivoxil: In Vitro Dissolution and in Vivo Bioavailability in Dogs
Cundy, K. C., Sue, I.-L., Visor, G. C., et al. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js970264s · Cited by 31
Murry, J. P., Higgins, J., Matthews, T. B., Huang, V. Y., Rompay, K. K. A. V., Pedersen, N. C., & North, T. W. (2002) · Journal of Virology · doi:10.1128/jvi.77.2.1120-1130.2003 · Cited by 29
Roy, C. J., Baker, R., Washburn, K., & Bray, M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2933-2937.2003 · Cited by 26
Hatse, S., Naesens, L. M. J., Clercq, E. D., & Balzarini, J. M. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00058-6 · Cited by 19
Self-citationUnexpected drug interactions and adverse events with antiretroviral drugs
Moyle, G. J., & Boffito, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16608-7 · Cited by 14
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Jordheim, L. P., Durantel, D., Zoulim, F., & Dumontet, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4010 · Cited by 1,211
Horsman, G. P., & Zechel, D. L. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00536 · Cited by 596
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Broder, S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.002 · Cited by 520
Metadata
- Authors
- Clercq, E. D., & Holý, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-11-01
- Volume
- 4
- Issue
- 11
- Pages
- 928-940
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1506669191
- Cited by
- 688
- References
- 57
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.